We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Physiomics Plc | LSE:PYC | London | Ordinary Share | GB00BDR6W943 | ORD 0.4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.15 | 13.04% | 1.30 | 1.20 | 1.40 | 1.30 | 1.15 | 1.15 | 1,153,587 | 13:26:25 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 597k | -477k | -0.0035 | -3.71 | 1.76M |
From Apr 2019 to Apr 2024
By Adria Calatayud
Physiomics PLC said Friday that it has been awarded further contracts of undisclosed value for projects with existing clients Bicycle Therapeutics PLC and Merck KGaA.
Physiomics, a U.K. oncology consultancy, said the project with U.K. biotech company Bicycle involves analysis of clinical data, while the deal with Germany's Merck is an extension to an existing project.
Both projects will be completed over the next four months, the company said.
Shares in Physiomics at 0839 GMT were up 3.7% at 7 pence.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
October 16, 2020 05:07 ET (09:07 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Physiomics Chart |
1 Month Physiomics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
